Apomorphine hydrochloride - Parkinson's disease
You are here : Home > Formulary Search > Apomorphine hydrochloride - Parkinson's disease
Status 1
- Pre-filled syringe
- Subcutaneous infusion
- Subcutaneous injection (sc)
Click on drug name for specific shared care document.
General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
Documentation
PAD Profile
Committee Recommendations (2)
Sublingual apomorphine has not yet been assessed for formulary status but it is on the APC work-plan.
This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives /options.
This advice will be updated after consideration by the APC. It is expected that an evaluation of this drug will be completed by April 2026.
.
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) have reviewed and agreed the updated apomorphine AMBER shared care document.
Other Indications
Below are listed other indications that Apomorphine hydrochloride is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Parkinson's disease.
- Amantadine hydrochloride
- Bromocriptine
- Cabergoline
- Clonazepam
- Co-beneldopa
- Co-careldopa
- Entacapone
- Foslevodopa with foscarbidopa
- Levodopa
- Levodopa with carbidopa and entacapone
- Melatonin
- Opicapone
- Orphenadrine hydrochloride
- Pergolide mesilate
- Pramipexole
- Procyclidine hydrochloride
- Rasagiline mesilate
- Ropinirole hydrochloride
- Rotigotine
- Safinamide
- Selegiline hydrochloride
- Tolcapone
- Trihexyphenidyl hydrochloride